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Abstract: BACKGROUND/AIM Cyclin-dependent kinases (CDKs) are crucial for cell cycle regulation,
and alterations in the cell cycle are often observed in human cancer. CDK4/6 in particular orchestrates
G1 phase progression and the G1/S transition. Here, we investigated the in vitro effects of the CDK4/6
inhibitor LEE011 in human neuroendocrine tumor cells. METHODS The human neuroendocrine tumor
cell lines BON1, QGP1, NCI-H727 and GOT1 were treated with different concentrations of LEE011 alone
and in combination with 5-fluorouracil and everolimus. RESULTS Cell viability decreased in a time- and
dose-dependent manner in BON1, QGP1, and NCI-H727 cells upon LEE011 treatment, whereas GOT1
cells were treatment resistant. Treatment sensitivity towards LEE011 was associated with the high
expression of cyclin D1 and Rb. LEE011 caused the dephosphorylation of Rb and a subsequent G1 phase
cell cycle arrest. Combined treatment with LEE011 and 5-fluorouracil or everolimus showed a significant
enhancement in the inhibition of cell viability when compared to single-substance treatments due to PI3K-
Akt-mTOR and Ras-Raf-MEK-ERK pathway downregulation and cooperative downregulation of cell
cycle components. However, LEE011 also exhibited antagonizing effects with 5-fluorouracil, protecting
NET cells from DNA-damaging chemotherapy by blocking PARP cleavage and caspase-3/7 activity.
CONCLUSIONS Our data demonstrate that the CDK 4/6 inhibitor LEE011 exhibits promising anti-
tumoral properties alone and in combination treatment approaches with 5-fluorouracil or everolimus in
human neuroendocrine tumor cell lines.
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LEE011 and 5-fluorouracil or everolimus showed a signifi-
cant enhancement in the inhibition of cell viability when 
compared to single-substance treatments due to PI3K-Akt-
mTOR and Ras-Raf-MEK-ERK pathway downregulation and 
cooperative downregulation of cell cycle components. How-
ever, LEE011 also exhibited antagonizing effects with 5-fluo-
rouracil, protecting NET cells from DNA-damaging chemo-
therapy by blocking PARP cleavage and caspase-3/7 activity. 
 Conclusions: Our data demonstrate that the CDK 4/6 inhibi-
tor LEE011 exhibits promising anti-tumoral properties alone 
and in combination treatment approaches with 5-fluoroura-
cil or everolimus in human neuroendocrine tumor cell lines. 
 © 2017 S. Karger AG, Basel 
 Introduction 
 Gastroenteropancreatic neuroendocrine tumors 
(GEP-NETs) are the second most common gastrointesti-
nal malignancy after colorectal cancer  [1] . Due to the 
variable cellular and tumor phenotypes of GEP-NETs, 
the clinical presentation is nonspecific; hence, the diag-
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 Abstract 
 Background/Aim: Cyclin-dependent kinases (CDKs) are cru-
cial for cell cycle regulation, and alterations in the cell cycle 
are often observed in human cancer. CDK4/6 in particular 
orchestrates G1 phase progression and the G1/S transition. 
Here, we investigated the in vitro  effects of the CDK4/6 in-
hibitor LEE011 in human neuroendocrine tumor cells.  Meth-
ods: The human neuroendocrine tumor cell lines BON1, 
QGP1, NCI-H727 and GOT1 were treated with different con-
centrations of LEE011 alone and in combination with 5-fluo-
r ouracil and everolimus.  Results: Cell viability decreased in a 
time- and dose-dependent manner in BON1, QGP1, and NCI-
H727 cells upon LEE011 treatment, whereas GOT1 cells were 
treatment resistant. Treatment sensitivity towards LEE011 
was associated with the high expression of cyclin D1 and Rb. 
LEE011 caused the dephosphorylation of Rb and a subse-
quent G1 phase cell cycle arrest. Combined treatment with 
 Received: October 10, 2016 
 Accepted after revision: February 11, 2017 
 Published online: February 23, 2017 
 Christoph Joseph Auernhammer 
 Department of Internal Medicine II, Campus Grosshadern, University Hospital  
 Ludwig-Maximilians University of Munich, Marchioninistrasse 15 
 DE–81377 Munich (Germany) 
 E-Mail christoph.auernhammer   @   med.uni-muenchen.de 








































































 Antitumoral Efficacy of LEE011 Neuroendocrinology 2018;106:58–73
DOI: 10.1159/000463386
59
nosis is often at a late and an advanced metastatic state  [1, 
2] . The paucity of successful targeting agents for GEP-
NETs is mostly due to the complexity and the rarity of 
GEP-NETs, as well as the intrinsic differences in malig-
nant potential because of their heterogeneity and the dis-
similar clinical presentation  [1, 3] . Current therapeutic 
approaches for GEP-NETs, such as biotherapy, molecular 
targeted therapy, chemotherapy, and peptide receptor ra-
dionuclide therapy are limited in their effectiveness; ergo, 
new strategies are urgently needed  [4] . The cyclin-depen-
dent kinases (CDKs) are the main regulators of the cell 
cycle transition and catalyze the phosphorylation of key 
proteins and transcription factors, and the aberrant ex-
pression of these CDKs due to gene mutation, amplifica-
tion or overexpression often leads to cancer cell forma-
tion  [5] . In addition to CDKs, their associated substrates 
(cyclins) are expressed in a spatiotemporal-dependent 
manner, enabling a controlled step-by-step cell cycle pro-
gression  [6] . In particular, the complexes cyclinD-CDK4 
and cyclinD-CDK6 regulate the G0–G1 transition in qui-
escent cells and the early G1 phase transition in prolifer-

























 Fig. 1. Proposed and simplified mode of ac-
tion of the CDK4/6 inhibitor LEE011 on 
the cell cycle.  a Activated cyclinD-CDK4/6-
Rb axis leads to G1/S cell cycle progression 
via the phosphorylation of Rb and subse-
quent activation of the transcription factor 
E2F.  b Blocking the cyclinD-CDK4/6-Rb 
axis leads to G1 phase cell cycle arrest 
through either the endogenous CDK4/6 in-













































































noblastoma protein (Rb) and thus activating the tran-
scription factor E2F  [7] . Activated E2F regulates 
transcription through G1/S phase by coordinating gene 
transcription of cell cycle progression-relevant proteins 
 [8] ( Fig. 1 a). The endogenous tumor suppressor p16INK4a 
(p16) blocks CDK4/6 and causes a permanent G1 phase 
arrest  [9] . Hence, the CDK4/6 inhibitor LEE011 (Novar-
tis, Basel) offers a very promising molecular targeting ap-
proach by selectively downregulating the proliferation-
associated cyclinD-CDK4/6-Rb axis ( Fig. 1 b). In various 
studies, the small molecule CDK4/6 inhibitor LEE011 has 
been shown to have antiproliferative characteristics with 
only weak side effects in comparison to previous nonse-
lective CDK inhibitors  [10] . Currently, a clinical phase 2 
trial with LEE011 is recruiting patients with advanced 
NETs of foregut origin (NCT02420691). Therefore, the 
phylogenetic homologues CDK4 and CDK6  [11] repre-
sent promising novel molecular targets for therapeutic 
NET treatments. Here, we investigate the effects of the 
CDK4/6 inhibitor LEE011 on different NET cell lines in 
vitro.
 Materials and Methods 
 Materials 
 Ribociclib (LEE011) and everolimus (Rad001) were provided 
by Novartis (Basel, Switzerland). 5-Fluorouracil (5-FU) was pur-
chased from Selleckchem (Houston, TX, USA). Everolimus and 
5-FU were diluted in dimethyl sulfoxide (DMSO; 10 m M stock so-
lution; Sigma, D8418). LEE011 was diluted in deionized water. 
Dulbecco’s Modified Eagle’s Medium – NutrientMixture F-12 (1: 
 1) (DMEM/F12) and penicillin/streptomycin were obtained from 
Gibco/Invitrogen (Karlsruhe, Germany). RPMI medium (with  L -
glutamine, NaCO 3 ) and phosphate-buffered saline (PBS) were 
purchased from Sigma, whereas trypsin-EDTA (10×) was acquired 
from PAA Laboratories (Cölbe, Germany). Fetal bovine serum 
(FBS) and amphotericin B were acquired from Biochrom (Berlin, 
Germany).
 Cell Culture 
 The human pancreatic NET (pNET) cell line BON1  [12] (kind-
ly provided by Prof. R. Göke, Marburg, Germany) and the pancre-
atic islet tumor cell line QGP1 (acquired from JCRB Cell Bank 
[Japanese Collection of Research Bioresources Cell Bank])  [13] 
were grown in DMEM/F12 (1: 1) supplemented with 10% FBS, 1% 
penicillin/streptomycin and 0.4% amphotericin B. Human bron-
chopulmonary neuroendocrine NCI-H727 (in all figures named 
H727) tumor cells  [14] (acquired from ATCC, Manassas, VA, 
USA) and human midgut carcinoid GOT1 cells  [15] (kindly pro-
vided by Prof. O. Nilsson, Sahlgrenska University Hospital, Göte-
borg, Sweden) were grown in RPMI medium supplemented with 
10% FBS, 1% penicillin/streptomycin and 0.4% amphotericin B. 
The GOT1 culture medium was additionally supplemented with 
5 μg/mL apo-transferrin and 0.135 IU/mL insulin. All human neu-
roendocrine cell lines were received and cultured as described pre-
viously  [16, 17] . The cells were tested and determined to be myco-
plasma free and incubated at 37  °  C and 5% CO 2 .
 Cell Viability Assessment 
 Cells were counted (Cellcounter Countess, Invitrogen, Germa-
ny), seeded, and grown for 24 h in 96-well plates at densities of 1,500 
(BON1), 2,000 (QGP1 and NCI-H727), and 30,000 (GOT1) cells 
per well. After 24 h, the cells were treated in 10% FBS with different 
concentrations of LEE011 alone and in combination with 10 n M 
everolimus or 5 μ M 5-FU, as previous studies had shown significant 
effects for the respective substance concentrations in NET cells in 
vitro  [16, 18] . Metabolic activity was measured with a CellTiter 96 ® 
Aq ueous One Solution cell viability assay (Promega, Madison, WI, 
USA) after 72 and 144 h of incubation. Then, the treated cells were 
incubated for 4 h with CellTiter 96 solution, and the absorbance was 
determined at 490 nm using an ELISA plate reader (Orion II; Ber-
thold Detection Systems, Pforzheim, Germany).
 Cell Cycle Analysis by Flow Cytometric Analysis 
 Cell cycle distribution was analyzed following the quick meth-
od from Nature Protocols “Analysis of Apoptosis by Propidium 
Iodide Staining and Flow Cytometry”  [19] (BD Accuri C6 Analy-
sis). Cells were cultured in 6-well plates (4 × 10 5 BON1 cells/well 
and 5 × 10 5 QGP1 and NCI-H727 cells/well) for 24 h in complete 
medium. After 24 h, the medium was replaced with fresh 10% FBS 
medium and incubated with 10 μ M LEE011 alone or in combina-
tion with 5 μ M 5-FU or 10 n M everolimus. After 72 h, the cells were 
washed with PBS and treated with 300 μL of trypsin at 37   °   C for 
5 min. Cells were collected and centrifuged at 2,000 rpm for 5 min. 
After another wash cycle with PBS, the cells were centrifuged 
again. The pellets were resuspended in 350 μL of propidium iodide, 
and 8 h later, 20,000 events from each sample were analyzed.
 Protein Extraction and Western Blotting 
 For Western blot experiments, 450,000 (BON1) and 600,000 
(QGP1 and NCI-H727) cells were seeded in 10-cm plates and 
grown for 24 h in complete medium. Then, the medium was re-
placed with fresh 10% FBS medium, and cells were incubated with 
different concentrations of LEE011 (500 n M and 10 μ M ) alone or 
in combination with 5-FU (5 μ M ) and everolimus (10 n M ). The 
incubation times proceeded for up to 72 h. After incubation, the 
cells were washed twice in cold PBS on ice and lysed in 500 μL of 
lysis buffer (M-PER Mammalian Protein Extraction Reagent con-
taining HALT protease and phosphatase inhibitor cocktail; Ther-
mo Scientific, Rockford, IL, USA). Lysates were centrifuged at 
13,000 rpm for 10 min. Supernatants were adjusted to the same 
protein concentration (30–50 μg/50 μL) (Rotiquant Universal; 
Carl Roth, Karlsruhe, Germany) and denatured in sodium dode cyl 
sulfate (SDS) sample buffer (0.25% Tris HCL, 40% glycerol, 2% 
SDS, 1% dithiothreitol, and bromophenol blue, pH 8.8). Equal 
amounts of protein were separated on an SDS polyacrylamide gel 
and electrotransferred for 60 min onto PVDF membranes (Im-
mobilone; Millipore, Eschborn, Germany) using a semi-dry West-
ern blot technique. After blocking in 2% skimmed milk powder, 
the membranes were incubated overnight at 4   °   C in appropriate 
dilutions of primary antibodies against pAKT (Ser473) (#4060), 
AKT (#2920), pERK1/2 (Thr202/Tyr204) (#4370), p4EBP1 (Ser65) 
(#9451), 4EBP1 (#9644), pRb (Ser780) (#9307), pCDK1 (Tyr15) 
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cyclin D3 (#2936), CDK4 (#12790), CDK6 (#13331), Chk1 (#2360), 
pChk2 (Ser19) (#2666), pChk2 (Thr68) (#6334), Chk2 (#6334), 
Parp (#9542), PCNA (#2586) (all from Cell Signaling Technology, 
Danvers, MA, USA), p16 INK4A (ab151303) (Abcam, Cambridge, 
UK), Rb (#614602) (Biolegend, San Diego, CA, USA), actin 
(A5441) (Sigma, St. Louis, CA, USA), and ERK1/2 (06-182) 
 (Merck-Millipore, Darmstadt, Germany). After washing in TBS, 
the membranes were incubated with a peroxidase-conjugated sec-
ondary antibody (1: 25,000) for 2 h. The blots were washed and 
immersed in the chemiluminescent substrate Super Signal West 
Dura (Thermo-Scientific), and images were taken with an ECL 
Chemocam Imager (INTAS, Göttingen, Germany).
 Caspase-3/7 Activity Assay 
 To measure the apoptotic activity, we used the Apo-One ho-
mogeneous caspase-3/7 assay kit (Promega, G7790). Therefore, we 
seeded 10,000 cells per well of each cell line and incubated for 
72 h in different concentrations of LEE011 alone or in combina-
tion with 5 μ M 5-FU and 10 n M everolimus. Cells were incubated 
for 72 h, and caspase-3/7 activity was assessed following the man-
ufacturer’s instructions.
 Statistical Analysis 
 The results are displayed as the mean ± standard deviation of 
the mean (SD) of at least 3 independently performed experiments. 
Each cell viability experiment consisted of at least 6 samples per 
substance concentration and incubation period. A priori tests con-
sidering the normal distribution and homogeneity of variances 
were performed applying the Kolmogorov-Smirnov test and Lev-
ene’s test using the SPSS statistical package (version 13.0 for Win-
dows, SPSS Inc., Chicago, IL, USA). When parametric criteria were 
met, an ANOVA comparison of means with a post hoc Tukey test 
or a 2-tailed  t test was performed; when nonparametric criteria 
were met, a Kruskal-Wallis test was performed followed by a 
Mann-Whitney test. Statistical significance was assessed at  p < 
0.05.
BON1
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 Fig. 2. The effect of different concentrations of LEE011 on cell sur-
vival of 4 different NET cell lines after 144 h of incubation. Human 
neuroendocrine pancreatic BON1, pancreatic islet QGP1, bron-
chopulmonary H727, and midgut GOT1 cells were incubated with 
LEE011 in a concentration range of 1 n M to 10 μ M for 144 h. The 
calculated means and standard deviation of at least 3 independent 
experiments are shown. Statistically significant differences in the 
results in comparison to control cells treated with DMSO 50 n M to 
10 μ M are represented by  * * *   p < 0.001. Data are presented as mean 
± SD. 
 Fig. 3. The 50% inhibitory concentration (IC 50 ) of LEE011 in 3 dif-













































































 LEE011 Inhibits Cellular Proliferation in Three out of 
Four NET Cell Lines 
 Neuroendocrine pancreatic BON1 cells, pancreatic is-
let QGP1 NET cells and bronchopulmonary NCI-H727 
NET cells showed significant treatment susceptibility in 
a time- and dose-dependent manner ( Fig. 2 ). GOT1 cells 
showed treatment resistance at all concentrations and 
incubation times tested. All 4 cell lines were incubated 
with LEE011 at a concentration range of 1 n M to 10 μ M . 
The most notable results were obtained after 144 h of in-
cubation with LEE011, where significant differences in 
all 3 cell lines in comparison to the Control DMSO-treat-
ed cells were reached with a concentration of only 50 n M . 
At a maximum concentration of 10 μ M , cell viability de-
creased in BON1 cells to 31.08 ± 6.13%, in QGP1 cells to 
47 ± 3.28%, and in NCI-H727 cells to 53.90 ± 8.74%. In 
QGP1 cells, an efficacy limit with a plateau effect was 
reached at a concentration of 1 μ M . Further concentra-
tion augmentation did not yield a significant survival de-
crease enhancement in QGP1 cells. The most sensitive 
cells towards the treatment, following the IC 50 values of 
each cell line after 144 h of incubation with LEE011 (1 
n M to 10 μ M ), were QGP1 (IC 50 = 1.2 μ M ), followed by 
BON1 cells (IC 50 = 2.6 μ M ) and NCI-H727 (IC 50 = 10.9 
μ M ) ( Fig. 3 ).
 Sensitivity to LEE011 Treatment Depends on Rb and 
Cyclin D1 Expression 
 Western blot analysis showed different baseline ex-
pression patterns of the cyclinD-CDK4/6-Rb axis in all 4 
NET cell lines ( Fig. 4 ). The tumor suppressor p16, Rb and 
cyclin D1 were stably expressed in neuroendocrine pan-
creatic BON1, pancreatic islet QGP1 and bronchopulmo-
nary NCI-H727 cells, whereas they were poorly expressed 
in GOT1 cells. CDK4 was very strongly expressed in 
GOT1 cells and less strongly expressed but present in all 
others. BON1 cells showed the highest CDK6 expression, 
followed by QGP1, NCI-H727, and GOT1 cells.
 LEE011 Causes G1 Phase Cell Cycle Arrest 
 In all 3 NET cell lines, flow cytometric analysis dem-
onstrated that LEE011 caused a dose-dependent increase 
in G1 phase cell cycle arrest after incubation with cells for 
72 h ( Fig. 5 ). In BON1 ( Fig. 5 a) and QGP1 ( Fig. 5 b) cells, 
a significant increase in G1 phase cell cycle arrest was ob-
served with concentrations as low as 1 μ M and observed 
in NCI-H727 ( Fig. 5 c) cells with concentrations as low as 
100 n M . At a maximum concentration of 10 μ M , the mean 
G1 phase percent of BON1 ( Fig. 5 a), QGP1 ( Fig. 5 b), and 
NCI-H727 ( Fig. 5 c) cells increased to 77.5 ± 2.1, 89.9 ± 
0.9, and 84.4 ± 4.9%, respectively. Consequently, the 
mean percent of cells in the G2 and S cell cycle phase sig-
nificantly decreased in all 3 cell lines ( Fig. 5 ).
 Combined Treatment with LEE011, 5-FU and 
Everolimus Showed More Efficacy Than 
Single-Substance Treatment in Decreasing NET
Cell Survival 
 For all 3 NET cell lines tested, the combined treatment 
led to significantly more effective results in mediating 
cell survival than single-substance treatment ( Fig. 6 ). At 
all incubation times and in all 3 cell lines, the combined 
treatment with LEE011 (500 n M ) and everolimus (10 n M ) 
showed significantly higher decreases in cell survival 
than each single-substance treatment ( Fig. 6 ). The com-
bined treatment with 5-FU was more effective only at 
some of the tested incubation times and in some of the 
cell lines ( Fig. 6 ). In BON1 cells, the combined treatment 
with 5-FU (5 μ M ) was only more effective after 72 h of 







 Fig. 4. Basal expression levels of proteins from the cyclinD-
CDK4/6-Rb axis in all 4 NET cell lines. The expression of p16, Rb, 
cyclin D1 CDK4, and CDK6 was evaluated by Western blot analy-
sis. A representative blot out of 3 independently performed ex-
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 Fig. 5. Cell cycle analysis of BON1 ( a ), 
QGP1 ( b ), and H727 ( c ) cells with different 
concentrations of LEE011 (10 n M to 10 μ M ) 
after 72 h of incubation measured by flow 
cytometric analysis. The calculated means 
and standard deviation of at least 3 inde-
pendent experiments are shown. Statisti-
cally significant differences in results in 
comparison to control cells treated with 10 
n M to 10 μ M DMSO are represented by 
 *    p < 0.05,  * *    p < 0.01, and  * * *    p < 0.001. 
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Effects on cell survival of combinational treatment with LEE011, 5-FU, and everolimus in BON1 cells
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Effects on cell survival of combinational treatment with LEE011, 5-FU, and everolimus in QGP1 cells
72 h of incubation





 Fig. 6. Effect of LEE011 on cell survival of 4 different NET cell lines 
after 72 and 144 h of incubation. Human neuroendocrine pancre-
atic BON1 ( a ) and pancreatic islet QGP1 ( b ), and bronchopulmo-
nary NCI-H727 ( c ) cells were incubated with LEE011 (100 and 500 
n M ) alone and in combination with 5-FU (5 μ M ) and everolimus 
(10 n M ) for 72 and 144 h. The calculated means and standard de-
viation of at least 3 independent experiments are shown. Statisti-
cally significant differences in the results in comparison to single-
substance treatments are shown;  *    p < 0.05,  * *    p < 0.01,  * * *    p < 
0.001. Data are presented as mean ± SD. 
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incubation with LEE011 (500 n M ), and cell survival de-
creased to 67.62 ± 5.73% ( Fig. 6 a). The combined treat-
ment with LEE011 (500 n M ) and everolimus (10 n M ) in 
BON1 cells showed significantly enhanced antiprolifera-
tive effects after 72 and 144 h, with a reduced mean cell 
survival of 58.07 ± 5.85 and 32.83 ± 8.89%, respectively 
( Fig.  6 a). Furthermore, in QGP1 cells, the combined 
treatment with LEE011 (100 and 500 n M ) and everoli-
mus (10 n M ) was more effective than single-substance 
treatment at both incubation times (72 and 144 h), and 
cell survival decreased to 73.33 ± 7.29 and 68.23 ± 8.70% 
after 72 h of incubation and 54.85 ± 7.98 and 43.21 ± 
5.29% after 144 h of incubation, respectively ( Fig. 6 b). 
Whereas the combined treatment with 5-FU in QGP1 
cells was only more effective at an incubation time of 144 
h and LEE011 concentration of 100 n M , with a mean sur-
vival of 63.40 ± 7.06% ( Fig. 6 b). Only in bronchopulmo-
nary NCI-H727 cells was the combination treatment 
with 5-FU more efficient than single-substance treat-
ment at both incubation times and both concentrations 
of LEE011, with a mean survival of 61.28 ± 4.59% (5-FU 
5 μ M + LEE011 100 n M ) and 59.94 ± 5.33% (5-FU 5 μ M 
+ LEE011 500 n M ) after 72 h and 50.72 ± 5.36% (5-FU 
5 μ M + LEE011 100 n M ) and 44.21 ± 6.34% (5-FU 5 μ M 
+ LEE011 500 n M ) after 144 h of incubation ( Fig. 6 c). 
Again, in NCI-H727 cells, the combined treatment with 
everolimus showed significantly better results than the 
respective single-substance treatments, with a mean cell 
survival of 69.80 ± 4.33% (everolimus 10 n M + LEE011 
100 n M ) and 67.21 ± 6.46% (everolimus 10 n M + LEE011 
500 n M ) after 72 h of incubation and 60.28 ± 6.51% 
(everolimus 10 n M + LEE011 100 n M ) and 54.35 ± 7.14% 
(everolimus 10 n M + LEE011 500 n M ) after 144 h of in-
cubation ( Fig. 6 c).
 LEE011 Blocks the Apoptotic Cell Death Mechanism 
through PARP and Caspase-3/7 Cleavage and Chk1 
Downregulation 
 Western blot analysis demonstrated the expression of 
PARP cleavage in human neuroendocrine pancreatic 
BON1, pancreatic islet QGP1 and bronchopulmonary 
NCI-H727 tumor cells when stimulated for 72 h with 
LEE011 (500 n M ) alone and in combination with 5-FU 
(5 μ M ) and everolimus (10 n M ) ( Fig. 7 a). In all 3 cell lines, 
LEE011 alone decreased PARP cleavage, whereas 5-FU 
induced PARP cleavage in comparison to control cells 
treated with DMSO. Everolimus alone induced only low 
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5-FU antagonizes the PARP-cleaving effects of 5-FU in 
all 3 cell lines. Furthermore, the weak PARP-cleaving ef-
fects of everolimus are also counteracted by LEE011. 
Mean caspase-3/7 activity was significantly decreased in 
all 3 cell lines after 72 h of incubation with LEE011 (500 
n M ) ( Fig. 7 b). Again, LEE011 in combination with 5-FU 
was shown to significantly counteract the induced cas-
pase-3/7 activity of 5-FU in BON1 and QGP1 cells 
( Fig.  7 b). Everolimus alone did not induce caspase-3/7 
activity, and the combination treatment with LEE011 and 
everolimus significantly lowered the already low cas-
pase-3/7 activity in BON1 and QGP1 cells ( Fig.  7 b). 
LEE011 treatment alone and in combination with 5-FU 
and everolimus lowered the expression and phosphoryla-
tion of Chk1/2 in all 3 NET cell lines analyzed ( Fig. 7 c).
 Combined Treatment with LEE011 and 5-FU or 
Everolimus Downregulates Two Major Proliferative 
Signaling Pathways in NETs: the PI3K-Akt-mTOR 
Pathway and Ras-Raf-MEK-ERK Pathway 
 Western blot analysis demonstrated the expression of 
PI3K-Akt-mTOR and Ras-Raf-MEK-ERK pathway com-
ponents in human neuroendocrine pancreatic BON1, 
pancreatic islet QGP1 and bronchopulmonary NCI-
H727 tumor cells when stimulated for 72 h with LEE011 
(500 n M ) alone and in combination with 5-FU (5 μ M ) or 
everolimus (10 n M ) ( Fig. 8 ). In BON1 and QGP1 cells, 
treatment with LEE011 alone phosphorylates Akt and 
Erk but dephosphorylates 4EBP1. In NCI-H727 cells, 
LEE011 alone has no effect on Akt phosphorylation, but 
p4EBP1 and pErk are downregulated. In all 3 cell lines, 
treatment with LEE011, 5-FU or everolimus resulted in 
unfavorable proproliferative phosphorylation of each 
component analyzed, but the combination treatment 



































































 Fig. 8. The effects of LEE011 (500 n M ) alone and in combination with 5-FU (5 μ M ) and everolimus (10 n M ) on 
components of the PI3K-Akt-mTOR and Ras-Raf-MEK-ERK signalling pathway in BON1, QGP1, and H727 cells 
after 72 h of incubation analyzed via Western blot. A representative blot from 3 independently performed ex-
periments is shown. 
 Fig. 7. The effects of LEE011 (500 n M ) alone and in combination 
with 5-FU (5 μ M ) and everolimus (10 n M ) on caspase-3/7 activity 
and PARP cleavage after 72 h of incubation.  a Western blot analy-
sis of PARP cleavage in NETs. A representative blot from 3 inde-
pendently performed experiments is shown.  b Caspase-3/7 activ-
ity in BON1, QGP1, and H727 cells. The calculated means and 
standard deviation of at least 3 independent experiments are 
shown. Statistically significant differences in the results in com-
parison to single-substance treatments are shown;  *    p < 0.05, 
 * *   p < 0.01,  * * * p < 0.001. Data are presented as mean ± SD.  c West-
ern blot analysis of Chk1 and Chk2 expression and phosphoryla-
tion in BON1, QGP1, and H727 cells. A representative blot from 3 





















































































































































































tagonized the unfavorable proproliferative phosphoryla-
tion of Akt, 4EBP1, and Erk when compared to the re-
spective single-substance treatments. The treatment with 
LEE011 and everolimus, in particular, showed a strong 
effect on dephosphorylation of Erk in all 3 cell lines.
 LEE011 Alone Downregulates the CyclinD-CDK4/
6-Rb Axis and Combined Treatment with 5-FU or 
Everolimus Affects Cell Cycle-Regulating Components 
 Western blot analysis revealed the expression level of 
cell cycle-relevant protein components in human neuro-
endocrine pancreatic BON1, pancreatic islet QGP1 and 
bronchopulmonary NCI-H727 tumor cells when stimu-
lated for 72 h with LEE011 (10 μ M ) alone and in combina-
tion treatment with LEE011 (500 n M ) and 5-FU (5 μ M ) or 
everolimus (10 n M ) ( Fig. 9 ). In all 3 cell lines, the endog-
enous CDK4/6 inhibitor p16 is upregulated in the com-
bination treatments with 5-FU and everolimus. In BON1 
and QGP1 cells, p16 is also upregulated upon single 
LEE011 (10 μ M ) treatment. Possibly due to feedback 
mechanisms, CDK4 and CDK6 show an increase in ex-
pression with LEE011 (10 μ M ) treatment. LEE011 at a 
 Fig. 9. The effects of LEE011 (500 n M ) alone and in combination with 5-FU (5 μ M ) and everolimus (10 n M ) on 
components of the cyclinD-CDK4/6-Rb axis, CDK1, and PCNA in BON1, QGP1, and H727 cells after 72 h of 
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concentration of 10 μ M decreases the cyclin B1, pRb, Rb, 
pCDK1 and CDK1 levels and increases the cyclin D1 lev-
el. In QGP1 and NCI-H727 cells, the combination treat-
ment with everolimus cooperatively downregulated cy-
clin B1, pRb, Rb, pCDK1, and CDK1. In BON1 cells, the 
combination treatment with everolimus only coopera-
tively downregulated Rb, but it attenuated the effects of 
everolimus on Cyclin B1, pCDK1 and CDK1. In all 3 cell 
lines, combined treatment with LEE011 and either 5-FU 
or everolimus attenuated the upregulation of cyclin D1. 
On the other hand, the 5-FU-mediated upregulation of 
cyclin B1, pRb, Rb, pCDK1, and CDK1 in QGP1 and 
NCI-H727 cells was attenuated by the combination treat-
ment with LEE011 (500 n M ). In all 3 cell lines, proliferat-
ing cell nuclear antigen (PCNA) was downregulated by 
either high concentrations of LEE011 (10 μ M ) alone or by 
combination treatment with everolimus (10 n M ) and was 
attenuated in QGP1 and NCI-H727 cells treated with a 
combination of LEE011 (500 n M ) and 5-FU (5 μ M ).
 Discussion 
 Therapeutic approaches against GEP-NETs are of lim-
ited efficacy, primarily due to their highly heterogeneous 
characteristics and the late-stage detection  [1, 3] ; ergo, 
new strategies are urgently needed  [4] . Nonspecific CDK 
inhibitors have been of limited efficacy in cancer treat-
ment, and they have exhibited highly cytotoxic side ef-
fects  [10] . The small molecule CDK4/6 inhibitor LEE011 
has demonstrated antiproliferative characteristics with 
only mild side effects  [10] . Therefore, in this in vitro 
study, we evaluated the novel and specific CDK 4/6 in-
hibitor LEE011 as a possible new molecular therapeutic 
strategy for NET treatment.
 Our results suggest a relationship between the level of 
Rb and cyclin D1 expression and sensitivity to LEE011 
treatment. The treatment-sensitive BON1, QGP1, and 
NCI-H727 cells showed elevated levels of Rb and cyclin 
D1 in comparison to LEE011 treatment-resistant GOT1 
cells with barely detectable Rb and cyclin D1 levels ( Fig. 4 ). 
Similar results were observed in an in vitro study with 
breast cancer cell lines, where CDK4/6 inhibitor (PD 
0332991) treatment-sensitive cell lines also expressed a 
high cyclin D1 and Rb protein level  [20] . A high expres-
sion level of the oncogene  Cyclin D1 has been shown to 
have a pathogenic role in parathyroid tumorigenesis and 
GEP-NETs  [21] . Hence, we suggest that GEP-NET treat-
ment with LEE011 has a high therapeutic relevance. In 
addition, high cyclin D1 expression levels were detected 
in a study that included 92 patients with pNETs  [22] . 
While loss of Rb is the reason for an augmented cell cycle 
and proliferation in some cancer types, in most cancer 
types, Rb remains in its wild-type state, including in NETs 
 [23–26] . Rb-proficient wild-type cell lines depend mostly 
on cyclinD-CDK4/6 regulation for proliferation and are 
likely to be susceptible to CDK4/6 inhibitory treatments 
 [27, 28] . Typical carcinoids (100%) and atypical carci-
noids (79%) of the lung exhibited Rb expression  [24] . In 
our study, GOT1 cells showed only minimally detectable 
expression levels of Rb and cyclin D1 ( Fig. 4 ). This stands 
in contrast to the clinical situation, as Rb and cyclin D1 
were found to be highly expressed in various NET tumor 
samples  [21, 22, 24] . A whole-exome comparison of pri-
mary well-differentiated NET samples versus BON, 
QGP1, and NCI-H727 cell lines showed substantial dif-
ferences in mutation rates and mutation patterns  [29, 30] . 
These data  [29, 30] demonstrate that available human 
NET cell lines might not adequately reflect the genetic 
and biological entities of well-differentiated NETs. There-
fore, the in vitro results of our study must be interpreted 
and extrapolated with caution with regard to the clinical 
situation. In a xenograft mouse model, tumor growth of 
the QGP1 cell line was also inhibited by the CDK4/6 in-
hibitor PD 0332991  [22] . Many studies also reported a 
low p16 expression level with high CDK4/6 inhibitor sus-
ceptibility  [20, 28, 31] . Here, we show that, on the one 
side, even a moderate expression of p16 (in BON1, QGP1, 
and NCI-H727 cells) ( Fig. 4 ) does not comprise the anti-
tumor efficiency of LEE011 ( Fig. 2 ), and on the other side, 
low p16 expression in GOT1 cells ( Fig. 4 ) did not sensitize 
cells to LEE011 treatment ( Fig. 2 ). CDK4/6 inhibition was 
suggested to be effective in tumor entities with CDK4 
overexpression or amplification  [10] . In mice, the devel-
opment of pancreatic islet or pituitary MEN-1 tumori-
genesis required a functional  Cdk4  gene  [32] . Further-
more, Tang et al.  [22] , found an upregulation of CDK4 in 
pNETs, which led to subsequent phosphorylational inac-
tivation of the retinoblastoma protein (Rb), and they de-
tected a  Cdk4 or  Cdk6 copy number increase in 19% of 
the cases in a genetic analysis of 26 pNETs. In our cell 
lines, CDK4 was expressed in all cell lines, but the expres-
sion levels of CDK4 and CDK6 were not markers for 
LEE011 treatment sensitivity ( Fig. 4 ). We suggest that the 
treatment resistance of GOT1 cells arises due to deficient 
Rb expression and low expression of cyclin D1 ( Fig. 4 ), 
which indicates that the cyclinD-CDK4/6-Rb axis is ne-
glectable for GOT1 cell proliferation  [10, 27] .
 In neuroendocrine pancreatic BON1, pancreatic islet 












































































served a time- and dose-dependent decrease in cellular 
survival with LEE011 treatment ( Fig. 2 ) and found sig-
nificant effects on NET cell cycle: A clear shift into G1 
phase cell cycle arrest was observed in all 3 NET cell lines 
tested ( Fig. 5 ). Similar results regarding a decrease in cell 
survival and G1 cell cycle arrest through inhibition of 
CDK4/6 with PD 0332991 were observed in breast cancer 
cell lines and ovarian cancer  [20, 28] . Wu et al.  [33] 2011 
also observed G1 phase cell cycle arrest due to CDK4 
knock down in different lung cancer cells. Unfortunately, 
LEE011 treatment caused a dose-dependent increase in 
the expression of oncogenic cyclin D1 and CDK4/6, pos-
sibly due to feedback loop mechanisms, which could lead 
to de novo treatment resistance ( Fig. 9 ). In estrogen-pos-
itive breast cancer cells, similar feedback mechanisms re-
garding cyclin D1 were detected, which led to cytostasis 
evasion  [34] . In a HER2-positive breast cancer mouse 
model, dual targeting prevailed against an acquired cyclin 
D1-CDK4 upregulation-mediated treatment resistance 
 [35] . Therefore, combination treatment strategies are a 
rational option, not only to enhance single substance ef-
ficacy but also to overcome possible treatment resistances 
and feedback loops.
 The chemotherapeutic agent 5-FU is a clinically ap-
plied drug that causes cytotoxic DNA damage and acti-
vates apoptosis  [36] . 5-FU and capecitabine are common-
ly used in the treatment of pNETs in various regimens, 
such as STZ/-FU, Cap/TEM, FOLFOX, or FOLFIRI  [37–
39] . The combined treatment with LEE011 and 5-FU was 
a rational combination choice to maximize the antipro-
liferative efficacy, as the 2 drugs target different pathways. 
As a consequence, the combination treatment showed a 
significant enhancement in cellular growth decrease 
( Fig. 6 ). A similar outcome was shown in a study with hu-
man ovarian cancer cell lines, where the CDK4/6 inhibi-
tor PD-0332991 enhanced the effects of chemotherapy 
 [28] . In addition, the combination treatment downregu-
lated oncogenic components of the PI3K-Akt-mTOR 
pathway and Ras-Raf-MEK-ERK pathway ( Fig. 8 ). Many 
studies indicate the importance of the Ras-Raf-MEK-
ERK and the PI3K-Akt-mTOR molecular signaling path-
way for NET cell growth, invasion, and proliferation  [16, 
40–46] . In addition, 5-FU showed cooperative downreg-
ulating effects with LEE011 on cell cycle components 
such as oncogenic cyclin D1 ( Fig. 9 ), which is often over-
expressed in GEP-NETs and influences tumorigenesis 
and cell proliferation in NETs  [21, 22] . Unfortunately, the 
ability of 5-FU to activate apoptotic mechanisms of cell 
death due to DNA damage  [36] seems to be attenuated by 
LEE011, as evidenced by the downregulation of proapop-
totic PARP cleavage ( Fig.  7 a) and caspase-3/7 activity 
( Fig. 7 b). The DNA damage response induces 2 cell cycle 
checkpoint kinases (Chk1 and Chk2) at G2/M and G1/S 
phase transition, respectively  [47] . LEE011 decreases the 
levels of Chk1/2 and their phosphorylation in NETs, and, 
as a result, the cell cycle is permanently arrested ( Fig. 7 c). 
Downregulation of Chk1 was also observed in a study 
with PD0332991  [48] . Although active Chk1 inhibition is 
correlated with an enhancement of 5-FU cytotoxicity 
 [49] , in combination with LEE011 the downregulation of 
Chk1/2 is due to the G1 phase cell cycle arrest rather than 
to specific Chk1-inhibiting effects, proving again the an-
tagonistic effects of LEE011 + 5-FU; CDK4/6 inhibition 
causes cell cycle arrest without passing beyond the restric-
tion point of Chk activation, hence abrogating the need 
for negative regulation of mitosis entry  [50] . Given our 
data, we assume that the permanent G1 phase cell cycle 
arrest as a consequence to CDK4/6 inhibition by LEE011 
might rescue the cells from undergoing apoptotic cell 
death in response to 5-FU treatment. Similar results are 
shown in a study with triple-negative breast cancer mod-
els, where CDK4/6 inhibition counteracted the cytotoxic 
response of doxorubicin, and in an in vivo study, where 
the DNA-damaging effects of carboplatin were also an-
tagonized by the CDK4/6 inhibitor  [48, 51, 52] . Hence, 
we recommend further investigation of the effects of 
5-FU in combination with CDK4/6 inhibitors to clarify 
possible antagonizing effects, and we expect the ongoing 
phase 1 study with paclitaxel and the CDK4/6 inhibitor 
palbociclib to examine this convoluted matter in the clin-
ic (NCT01320592).
 The PI3K-Akt-mTOR pathway is an important and 
often constitutively activated pathway in NETs  [16, 46] . 
The mTOR inhibitor everolimus has been investigated in 
NETs in several clinical phase 3 trials  [53] . Everolimus 
has been approved for the treatment of advanced pNETs 
 [54–57] and for the treatment of gastrointestinal NETs 
and lung NETs  [53] , and it is one of the established treat-
ment options according to ENETS guidelines  [53] . Sin-
gle-substance treatment with everolimus has been shown 
to lead to resistance mechanisms in many tumor entities, 
including pNETs  [58–61] . Dual-targeted therapy ap-
proaches to overcome possible resistance mechanisms 
and feedback loops have shown promising results in 
NETs  [40, 62] . In PI3K inhibitor-resistant cancer cells, 
combined treatment with a CDK4/6 inhibitor re-sensi-
tized cancer cells to PI3K inhibition  [63] . The PI3K-Akt-
mTOR pathway is also a crucial molecular signaling path-
way in promoting cyclinD-CDK4/6-dependent prolifera-
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point  [64] . Combined treatment with the mTORC1-
downregulating everolimus significantly enhanced the 
decrease in cellular survival in all NET cell lines tested 
( Fig. 6 ). Similar effects on cell survival were obtained in a 
study with breast cancer, where the combination of a 
CDK4/6 inhibitor with a PI3K inhibitor synergistically 
inhibited tumor cell viability  [63] . Additionally, the com-
bination treatment with everolimus downregulated the 
oncogenic PI3K-Akt-mTOR pathway and the Ras-Raf-
MEK-ERK pathway ( Fig. 8 ) and showed cooperative ef-
fects on the downregulation of cell cycle components 
( Fig. 9 ). Similar to the combination treatment with 5-FU, 
the combination of LEE011 and everolimus also showed 
cooperative effects in blocking oncogenic cyclin D1 
( Fig. 9 )  [21, 22] . In addition, the endogenous CDK4/6 in-
hibitor p16 is upregulated upon combined LEE011 and 
everolimus treatment in all 3 cell lines ( Fig. 9 ), supporting 
the exogenous CDK4/6 inhibition of LEE011. Further-
more, the combination treatment with everolimus and 
LEE011 showed no crucial antagonizing effects on apop-
totic cell death mechanisms ( Fig. 7 ). mTOR activity has 
been shown to have little association with apoptotic sig-
nalling mechanisms, and only high doses of everolimus 
could induce apoptotic cell death mechanisms in NETs 
 [16, 65] . In addition, the combination treatment (LEE011 
+ everolimus)-mediated decrease in Chk expression and 
phosphorylation ( Fig. 7 c) had no appreciable impact on 
treatment efficiency, as everolimus is a molecular target-
ing substance, not a DNA damaging agent  [66] . Further-
more, the combination treatment with everolimus showed 
strong agonistic effects with LEE011 in PCNA inhibition 
( Fig. 9 ). PCNA is a DNA polymerase accessory protein 
that is implicated in different cellular processes, such as 
DNA replication, DNA repair, and cell cycle control  [67] . 
PCNA has been found to actively bind to some Cyclins 
and their corresponding kinases to support cell cycle pro-
gression and DNA replication  [67, 68] . Inhibition of 
PCNA due to either endogenous p21 or exogenous in-
hibitors leads to immediate cell cycle arrest  [69, 70] . In-
terestingly, everolimus was shown to increase G1 phase 
cell cycle arrest in NET cells, assuming a possible rein-
forcing effect for combination with CDK4/6 inhibitors 
such as LEE011  [16] . Current clinical phase 1b studies are 
investigating the combination of LEE011 and everolimus 
in patients with breast cancer (NCT01857193 and 
NCT02732119). Taken together, our data regarding the 
combination treatment with LEE011 and everolimus in 
NETs in vitro suggest that this dual-targeting strategy 
may be an effective regimen for a novel therapeutic strat-
egy against NETs.
 Conclusion 
 We demonstrated that the highly selective CDK4/6 in-
hibitor LEE011 exerts significant antitumoral efficacy in 
NET cell lines in vitro, either alone or in a dual-targeting 
approach together with 5-fluorouracil or everolimus. The 
small molecule CDK4/6 inhibitor LEE011 effectively 
blocks cellular proliferation through downregulation of 
the cyclinD-CDK4/6-Rb axis. Thus, CDK4/6 inhibition 
with LEE011 might be an effective new therapeutic regi-
men for NETs. Currently, a clinical phase 2 trial with 
LEE011 is recruiting patients with advanced NETs of 
foregut origin (NCT02420691), and another clinical 
phase 2 trial is recruiting patients with CDK4/6 pathway-
activated tumors (NCT02187783).
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